What Researchers Did
Chinese researchers enrolled 120 patients with idiopathic sudden sensorineural hearing loss and divided them into a medication-only group and an HBOT-plus-medication group, measuring both hearing thresholds and inflammatory markers before and after treatment.
What They Found
The HBOT group showed significantly better hearing improvement than the medication-only group. Both groups had elevated TLR4, NF-kB, and TNF-alpha levels before treatment; after treatment, these inflammatory markers dropped significantly more in the HBOT group, suggesting HBOT reduces cochlear inflammation through TLR4/NF-kB signaling pathways.
What This Means for Canadian Patients
For Canadians who experience sudden unexplained hearing loss, this study adds to the evidence that HBOT improves outcomes beyond what medication alone achieves, and identifies the anti-inflammatory mechanism behind the benefit.
Canadian Relevance
No direct Canadian connection identified. Sudden hearing loss affects approximately 1 in 5,000 Canadians annually; understanding the molecular basis for HBOT benefit could help identify which patients are most likely to respond.
Study Limitations
The study was conducted in a single Chinese centre with a specific patient population; medication protocols used may differ from standard North American practice, limiting direct comparability.